Chrisandra L Shufelt1, JoAnn E Manson2,3. 1. Barbra Streisand Women's Heart Center, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. 2. Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 3. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Abstract
CONTEXT: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery. METHODS: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy," "transdermal," "estradiol," "conjugated estrogens," "bioidentical," "cardiovascular disease," "lipoproteins," "glucose," "progestogens," "low dose." RESULTS: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin, and CVD risk; however, the addition of progestogens blunts the lipid-related effects. The progestogen with the smallest attenuating effect is micronized progesterone. Transdermal estrogens have less effect on coagulation, inflammation, and lipids than oral estrogens and observational studies suggest they pose a lower risk of venous thromboembolism and stroke than oral estrogens. Clinical effects of hormones were not consistently dose dependent. CONCLUSIONS: Although HT continues to have an important role in menopause management, it is not recommended for primary or secondary CVD prevention. Different formulations, doses, and routes of delivery of HT have different effects on cardiometabolic markers and risks of clinical CVD events. However, long-term trials evaluating clinical outcomes with transdermal and other alternate HT regimens are limited.
CONTEXT: This mini-review provides an overview of menopausal hormone therapy (HT) and cardiovascular disease (CVD) risk, with a focus on the role of hormone formulation, dose, and route of delivery. METHODS: This summary is based on authors' knowledge in the field of menopausal HT and supplemented by a PubMed search using the terms "menopause hormone therapy," "transdermal," "estradiol," "conjugated estrogens," "bioidentical," "cardiovascular disease," "lipoproteins," "glucose," "progestogens," "low dose." RESULTS: Available evidence indicates that oral unopposed estrogens have a favorable effect on lipoprotein levels, glycemia, insulin, and CVD risk; however, the addition of progestogens blunts the lipid-related effects. The progestogen with the smallest attenuating effect is micronized progesterone. Transdermal estrogens have less effect on coagulation, inflammation, and lipids than oral estrogens and observational studies suggest they pose a lower risk of venous thromboembolism and stroke than oral estrogens. Clinical effects of hormones were not consistently dose dependent. CONCLUSIONS: Although HT continues to have an important role in menopause management, it is not recommended for primary or secondary CVD prevention. Different formulations, doses, and routes of delivery of HT have different effects on cardiometabolic markers and risks of clinical CVD events. However, long-term trials evaluating clinical outcomes with transdermal and other alternate HT regimens are limited.
Authors: Marinka S Post; M Christella; L G D Thomassen; Marius J van der Mooren; W Marchien van Baal; Jan Rosing; Peter Kenemans; Coen D A Stehouwer Journal: Arterioscler Thromb Vasc Biol Date: 2003-05-01 Impact factor: 8.311
Authors: H N Hodis; W J Mack; R A Lobo; D Shoupe; A Sevanian; P R Mahrer; R H Selzer; C R Liu Cr; C H Liu Ch; S P Azen Journal: Ann Intern Med Date: 2001-12-04 Impact factor: 25.391
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Jan L Shifren; Nader Rifai; Sophie Desindes; Marilyn McIlwain; Gheorghe Doros; Norman A Mazer Journal: J Clin Endocrinol Metab Date: 2008-02-26 Impact factor: 5.958
Authors: Cynthia A Stuenkel; Susan R Davis; Anne Gompel; Mary Ann Lumsden; M Hassan Murad; JoAnn V Pinkerton; Richard J Santen Journal: J Clin Endocrinol Metab Date: 2015-10-07 Impact factor: 5.958
Authors: Jacques E Rossouw; Mary Cushman; Philip Greenland; Donald M Lloyd-Jones; Paul Bray; Charles Kooperberg; Mary Pettinger; Jennifer Robinson; Susan Hendrix; Judith Hsia Journal: Arch Intern Med Date: 2008-11-10
Authors: Cindy Z Kalenga; Jacqueline L Hay; Kevin F Boreskie; Todd A Duhamel; Jennifer M MacRae; Amy Metcalfe; Kara A Nerenberg; Magali Robert; Sofia B Ahmed Journal: Front Cardiovasc Med Date: 2022-06-10
Authors: Emanuel Guajardo-Correa; Juan Francisco Silva-Agüero; Ximena Calle; Mario Chiong; Mauricio Henríquez; Gerardo García-Rivas; Mauricio Latorre; Valentina Parra Journal: Front Cell Dev Biol Date: 2022-09-14